Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M

Rapport Therapeutics, Inc.

Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).
End-of-Phase 2 FDA meeting by end 2025; two Phase 3 FOS trials to start Q3 2026.
Q3 net loss $26.9M (vs $17.5M YoY); R&D $22.3M, G&A $7.7M.
Cash, equivalents, and ST investments $513.0M; includes $269.4M net from September public offering.
Bipolar mania Phase 2 enrolling; topline expected H1 2027. DPNP trial on FDA clinical hold; update Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.